24 November 2022 – 12:43
Brussels, Nov 24 (EFE).- The European Commission (EC) has signed, through the Health Preparedness and Response Authority (HERA), a joint procurement contract for the supply of some 3.5 million Paxlovid treatments against covid-19, reported the community Executive this Thursday.
The contract was signed on Wednesday with the pharmaceutical company Pfizer and its initial duration will be twelve months.
Paxlovid is an oral SARS-CoV-2 protease inhibitor treatment for people at risk of developing severe disease.
The treatment is considered to be effective against the currently circulating dominant strains of the virus.
Thirteen Member States of the European Union (EU) and candidates for accession participate in this public acquisition, said the EC.
They will be able to purchase up to 3,427,517 five-day treatments of Paxlovid, which can be used for the treatment of covid in adults who do not require supplemental oxygen and who are at high risk of worsening the disease.
The EU Joint Procurement Agreement offers thirty-six participating countries the possibility to jointly procure medical countermeasures as an alternative or complement to public procurement at the national level.
European Health Commissioner Stella Kyriakides said that “therapeutic options are, along with safe and effective vaccines, a key pillar of our efforts to tackle Covid-19.”
“We have worked closely with our Member States to ensure safe and effective therapeutic treatment to help protect and treat those most at risk of covid-19. These efforts will continue to be crucial in the coming weeks and months, since the epidemiological situation continues to evolve during the winter”, said the commissioner. EFE
(More information on the European Union at euroefe.euractiv.es)
� EFE 2022. The redistribution and redistribution of all or part of the contents of Efe services is expressly prohibited, without the prior and express consent of Agencia EFE SA